Inhibikase Therapeutics Files 8-K on Agreements and Personnel Changes
Ticker: IKT · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1750149
| Field | Detail |
|---|---|
| Company | Inhibikase Therapeutics, INC. (IKT) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $110 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, personnel-change, corporate-action
Related Tickers: IBK
TL;DR
IBK filed an 8-K on 10/21, reporting new deals and exec changes. Watch for details.
AI Summary
Inhibikase Therapeutics, Inc. filed an 8-K on October 21, 2024, reporting on the entry into a material definitive agreement, the departure of directors or officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the date of the earliest event reported as October 21, 2024.
Why It Matters
This 8-K filing signals significant corporate activity, including potential new agreements and changes in leadership or compensation structures, which could impact the company's strategic direction and investor outlook.
Risk Assessment
Risk Level: medium — The filing indicates material definitive agreements and changes in officers/directors, which can introduce uncertainty or signal strategic shifts.
Key Numbers
- 001-39676 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-3407249 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- October 21, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3350 Riverwood Parkway SE, Suite 1900 (address) — Principal Executive Offices
- Atlanta, Georgia (location) — Principal Executive Offices City and State
- 30339 (zip_code) — Principal Executive Offices Zip Code
FAQ
What specific material definitive agreement was entered into by Inhibikase Therapeutics?
The filing indicates the entry into a material definitive agreement but does not specify the details of the agreement in the provided text.
Who are the directors or officers that have departed from Inhibikase Therapeutics?
The filing mentions the departure of directors or certain officers but does not name the individuals involved in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes compensatory arrangements for certain officers but does not provide specific details in the excerpt.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 21, 2024.
What is the primary business of Inhibikase Therapeutics, Inc. according to the filing?
Inhibikase Therapeutics, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 1,260 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2024-10-21 21:13:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
- $110 million — ayable by the Company, of approximately $110 million. The material terms of the Registrati
Filing Documents
- d902445d8k.htm (8-K) — 33KB
- d902445dex991.htm (EX-99.1) — 19KB
- g902445g1021152604152.jpg (GRAPHIC) — 3KB
- 0001193125-24-240603.txt ( ) — 190KB
- ikt-20241021.xsd (EX-101.SCH) — 3KB
- ikt-20241021_lab.xml (EX-101.LAB) — 18KB
- ikt-20241021_pre.xml (EX-101.PRE) — 11KB
- d902445d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Press Release dated October 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 21, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer